Biomarkers of Common Eye Diseases

• Conditions: Uveitis; Age-related Macular Degeneration; Diabetic Retinopathy; VKH Syndrome; Polypoidal Choroidal Vasculopathy; Behçet Disease
• Interventions: Other: Collection of blood samples

• Registration Number: NCT04101604
• Lead Sponsor: Sun Yat-sen University

Brief Summary

To identify biomarkers of common eye diseases based on single-cell sequencing technologies using PBMC samples. These diseases include uveitis, diabetic retinopathy, age-related macular degeneration and polypoid choroidal vasculopathy. Our study may provide new insight into the underlying mechanisms, and reveal novel predictors and intervention targets for the diagnosis, prognosis and treatment of these diseases.

Detailed Description

The pathogenesis of common eye diseases such as uveitis (including Behcet's disease (BD) and Vogt-Koyanagi-Harada disease (VKH)), diabetic retinopathy (DR), age-related macular degeneration (AMD) and polypoid choroidal vasculopathy (PCV) remains unknown. Although immunosuppressants, anti-vascular endothelial growth factor (VEGF) agents, and pars plana vitrectomy (PPV) have been widely used for treatment, the current therapeutic options are limited. In addition, there is a lack of biomarkers to indicate the prognosis and treatment response of these diseases. The aim of this study is to identify biomarkers and to provide a new target for individualized diagnosis and treatment of common eye diseases based on single cell sequencing technology.

Study Timeline

• Status Verified: 2019-09
• Study First Submitted: 2019-09-20
• Study First Submitted QC: 2019-09-23
• Study First Posted: 2019-09-24
• Last Update Submitted: 2019-09-25
• Study Start: 2019-09-26
• Last Update Posted: 2019-09-27
• Primary Completion: 2020-10-01
• Study Completion: 2021-10-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Healthy subjects	Collection of blood samples	Collection of blood samples and clinical information
Patients with VKH, BD, DR, AMD, or PCV	Collection of blood samples	Collection of blood samples and clinical information from patients with VKH, BD, DR, AMD, or PCV

Primary Outcome Measures

Name	Time	Method
Peripheral blood mononuclear cell (PBMC) signatures	1 year	PBMC signatures, derived from single cell sequencing and mass spectrometry, will be compared for the same patient before and after treatment, among patients of different symptoms and severity measures, and also between patients and healthy subjects. Upon these comparisons, biomarkers will be established for the patient population.

Secondary Outcome Measures

Name	Time	Method
PBMC cell types frequencies	1 year	PBMC cell types frequencies, derived from single cell sequencing and mass spectrometry, will be compared for the same patient before and after treatment, among patients of different symptoms and severity measures, and also between patients and healthy subjects.

Trial Locations

Locations (1)

Zhognshan Ophthalmic Center, Sun Yat-sen University; 🇨🇳 Guangzhou, Guangdong, China